

Catalytic Antibodies

Edited by Ehud Keinan



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Catalytic Antibodies
Edited by Ehud Keinan

Further Titles of Interest

C. Niemeyer, C. Mirkin (eds.)

Nanobiotechnology – Concepts, Applications and Perspectives

2004

ISBN 3-527-30658-7

A. S. Bommarius, B. Riebel

Biocatalysis – Fundamentals and Applications

2004

ISBN 3-527-30344-8

K. Drauz, H. Waldmann (eds.)

Enzyme Catalysis in Organic Synthesis (2nd Edition)

2002

ISBN 3-527-29949-1

S. Brakmann, K. Johnsson (eds.)

Directed Molecular Evolution of Proteins

2002

ISBN 3-527-30423-1

Catalytic Antibodies

Edited by Ehud Keinan



WILEY-
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

Prof. Dr. Ehud Keinan
Department of Chemistry
Technion-Israel Institute of Technology
Technion City
Haifa 32000
Israel
keinan@technix.technion.ac.il

and
The Scripps Research Institute
Department of Molecular Biology
and
The Skaggs Institute for Chemical Biology
10550 North Torrey Pines Road
La Jolla, CA 92037
USA
keinan@scripps.edu

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.:
applied for

British Library Cataloguing-in-Publication Data:
A catalogue record for this book is available from the British Library.

**Bibliographic information published by
Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>

© 2005 WILEY-VCH Verlag GmbH & Co KGaA,
Weinheim

Printed on acid-free paper

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.


Composition Steingraeber Satztechnik GmbH,
Dossenheim

Printing Strauss GmbH, Mörlenbach

Bookbinding Litges & Dopf Buchbinderei GmbH,
Heppenheim

Printed in the Federal Republic of Germany

ISBN 3-527-30688-9



”וְכָתְתוּ חֶרְבוֹתָם לְאֵתִים,
 וְחֲנִיתוֹתֵיהֶם לְמִזְמְרוֹת ...”
 (ישעיהו ב,ד)

*“And they shall beat their swords
 into plowshares, and their spears
 into pruning-hooks ...”*

Isaiah (2:4)

Antibodies represent the major weapon our body utilizes to attack foreign invaders. The idea of chemists using antibodies to catalyze their non-biological reactions is reminiscent of the biblical metaphor of a military weapon being converted to a working tool. This phrase from Isaiah inspired Mordecai Ardon (1896–1992), whose monumental stained glass windows adorn the Jewish National and University Library on the campus of the Hebrew University of Jerusalem. Photo courtesy of the Hebrew University.

Foreword

It is not our intent here to review the many accomplishments of the field of antibody catalysis. The chapters contained in this volume amply attest to the vigor and accomplishments of the field. Rather we will attempt to extract some of the general principles that have and continue to guide the field.

The first issues concern why one would attempt to make enzymes since there are already some 4000 enzymes known that cover many chemical transformations that one might desire to accomplish. The simple answer is that there are many transformations that existing enzymes do not cover and one might wish to have enzymes for these transformations. However, there is a much deeper answer to this question that goes to the heart of the field and, indeed, is the centerpiece of chemistry. Chemists make things in order to understand the rules of chemistry. For instance, the object of natural product chemistry is not to obtain carloads of material, but rather to understand the general principles that govern how atoms and molecules interact. One learns from both the successes and failures of attempts to accomplish a given transformation. Likewise, if we are to understand the complex chemical engines that are protein enzymes we must ultimately make them. As with natural products, we can learn from both successes and failures. In every case when the binding energy of antigen-antibody union is converted to catalysis, we can state that we know a route by which the transformation under consideration can occur. The initial problem – that one didn't know in detail exactly how the transition state is bound – has largely been obviated by the many crystal structures of catalytic antibodies bound to their transition state analogues. Of course, a catalytic antibody tells one *a* way that a given transformation can proceed, but not necessarily *the* way that a natural enzyme might accomplish the same transformation. The fact that proteins can accomplish the same transformation by a variety of routes is in of itself very interesting and one can only wonder why certain roads were not taken by evolution especially if they are isoenergetic.

So what have we learned? The first very large lesson is that it is not very difficult to generate protein catalysts so long as one correctly understands some of the general chemical principles of the reaction. In stating that it is easy to obtain catalysis we are not making a statement about overall efficiency, but for now are only concerned about starting with binding energy and winding up with catalysis. The lessons that

one derives from the experimental conversion of binding energy to catalysis in real time speaks most generally to the large subject of enzyme evolution. This is because evolution can improve things so long as the function is useful and, thus, the fact that it is rather easy to get catalysis started in the confines of a generic protein-binding pocket gives a selectable function. One of the main insights upon which the field of antibody catalysis was founded is that even a combinatorial library as large as the antibody repertoire was, when used randomly, not large enough to achieve catalysis in real time. Thus, relative to the evolutionary time scale, the process was shortened by millions to billions of years by programming the binding with detailed chemical instructions. These instructions were given, of course, by use of transition state analogues as antigens. The process by which the early antibody catalysts were generated is not precisely identical to evolution for two reasons. First, there is presumably no process in evolution in which a concert of chemical instructions is given at once. Second, screening rather than selection was used to find the early catalysts. Thus, unlike the real time induction of antibody catalysts, evolution does not need instruction because it has time and selection on its side. However, one can assume that immunization with a transition state analogue is simply a device that shortens the time to reach a point that evolution would come to anyway. From this vantage point, antibody catalysis can teach us much about the evolution of enzymes. In the simplest of terms, immunization with a transition state analogue does select for a concert of binding parameters such as the size of the binding pocket, the geometrical arrangement, of protein functionalities around the transition state, and the distribution of charges. Presumably evolution would have to do the same and, in this sense, these parameters are like state functions in that their overall energetics are independent of the pathway by which they were formed. Because we understand that proteins are complex and dynamic entities, we would not expect one-step perfection even though a proper concert of favorable binding interactions has been achieved. In this sense it is paradoxical that we can learn the most about enzyme evolution from the imperfection of antibody catalysts. This is because we can isolate binding parameters and learn what they worth in terms of rate acceleration. Further, because of the fact that antibodies are easy to engineer we can make stepwise improvements and study how they affect catalysis. Finally, the focus here on imperfect enzymes is not to say that, as we will see later, enzymes that rival natural catalysts have not been achieved.

The extraction of information that relates binding to catalysis depends on how many different binding motifs can be generated because this becomes the database from which the general principles are extracted. Fortunately, the antibody repertoire is sufficiently large that a sizeable database of binding interactions is achieved. Another feature that needs to be recognized derives from the fact that the induction of an immune is, itself, an evolutionary process that selects for binding energy. Thus, in making a database on the best way to bind to organic functionalities, we are also learning about the permitted and most successful ways that substrates and transition states might be bound. One of the early difficulties of the field was that the fine details of how binding occurred were not totally controlled by the experimenter. While this is still somewhat the case, this has largely been obviated by the bait and switch strategy and covalent immunization.

One of the most startling lessons from the field concerns how precisely a complex enzyme mechanism can be copied into another protein with a completely different fold and presumably dynamic repertoire. This was seen in the ease by which aldolase antibody catalysts that proceed by an enamine mechanism were generated by immunization with a simple 1,3-diketone antigen to select for a reactive lysine in the antibody active site. The mechanism and rate acceleration of these antibody aldolases are nearly identical to nature's own enzymes. One interesting side point that came out of these studies concerns the vigor with which immunological evolution drives toward binding energy even to the point of taking covalent options when they are available. Thus, even though a diketone antigen "offered" the opportunity for covalent binding if a lysine with a perturbed pK_a appeared by mutation, there were many other ways that binding energy could be achieved without resorting to the covalent option (for instance by simple binding to the benzene ring that was also present in the hapten). The fact that most antibodies mutated to express a rare lysine that is not present in the germ line speaks to the fact that antibody evolution is, as expected, a chemistry driven process but also one whose chemistry is only limited by opportunity so long as the reaction in question increases binding energy beyond that which can be achieved by a concert of non-covalent interactions. In other words, any chemical reaction that can happen will.

One of the largest lessons about proteins and catalysis came from an antibody that is not a catalyst and, thus, is not covered in this volume. Several of us reasoned that the time had come to use the binding energy of antibodies to perturb electronically excited states in the same way that thermal transition states have been studied in the field so far. To attempt this, antibodies were made to stilbene. Remarkably, even though these antibodies were not "taught" about the excited state, when irradiated with U.V light they adapted to and perturbed the excited state of stilbene and emitted intense blue light. These antibodies were called "blue fluorescent antibodies". This effect means that proteins that bind to ground states can adapt to high-energy states of the ligand with sufficient energy to perturb the excited state surface. This is probably a general property of proteins and may explain how enzymes bind to ground state substrates while also maintaining the property of adapting to transition states. Again we see a lesson from antibodies that goes to the centerpiece of protein catalysis.

In terms of breaking news, recent events have demonstrated that all antibodies have the catalytic potential to generate highly reactive oxygen species including ozone and a masked form of the hydroxyl radical. This may be the most potent effector function of antibodies ever discovered. Thus, this preface ends with a remarkable irony. The able workers whose beautiful experiments are detailed in this volume turned antibodies into enzymes to learn more about natural enzymes only to ultimately find out that antibodies were natural enzymes all along!

Richard A. Lerner and Peter G. Schultz

The Scripps Research Institute and
The Skaggs Institute for Chemical Biology,
Department of Chemistry,
10550 N. Torrey Pines Road, La Jolla, CA 92037

Table of Contents

1	Immunological Evolution of Catalysis 1
	<i>Jun Yin, Peter G. Schultz</i>
1.1	Introduction 1
1.2	Parallels between Antibody and Enzyme Evolution 1
1.3	Evolution of Catalytic Antibodies 3
1.4	Ferrochelataase Antibody 7G12 – Evolution of the Strain Mechanism 3
1.5	Esterase Antibody 48G7 – Effect of Distant Mutations on Catalysis 15
1.6	Sulfur Oxidase Antibody 28B4 – Incremental Changes in Evolution 18
1.7	Oxy-Cope Antibody AZ28 – Evolution of Conformational Diversity in Catalysis 22
1.8	Diels-Alderase Antibody 39A11 – Evolution of a Polyspecific Antibody combining Site 25
1.9	Conclusions 26 References 28
2	Critical Analysis of Antibody Catalysis 30
	<i>Donald Hilvert</i>
2.1	Introduction 30
2.2	Exploiting Antibodies as Catalysts 30
2.3	Catalytic Efficiency 31
2.4	Hapten Design 33
2.5	Representative Catalytic Antibodies 34
2.5.1	Proximity Effects 34
2.5.1.1	Sigmatropic Rearrangements 34
2.5.1.2	Cycloadditions 38
2.5.2	Strain 43
2.5.2.1	Ferrochelataase Mimics 43
2.5.2.2	Other Systems 46
2.5.3	Electrostatic Catalysis 46
2.5.3.1	Acyl Transfer Reactions 46
2.5.4	Functional Groups 53

2.5.4.1	Aldolases	54
2.6	Perspectives	57
2.6.1	General Lessons from Comparisons of Enzymes and Antibodies	57
2.6.2	How efficient does catalysis need to be?	58
2.6.3	Strategies for Optimizing Efficiency	59
2.6.3.1	Better Haptens	60
2.6.3.2	Screening	61
2.6.3.3	Engineering	61
2.6.3.4	Selection	62
2.6.3.5	Other Scaffolds	62
2.7	Conclusions	63
	References	65

3 Theoretical Studies of Antibody Catalysis 72

Dean J. Tantillo, Andrew G. Leach, Xiyun Zhang, K. N. Houk

3.1	Introduction	72
3.2	Questions Subject to Theoretical Elucidation	73
3.2.1	Predicting Antibody Structure from Sequence	73
3.2.2	Predicting Binding Modes and Binding Energies	74
3.2.3	Understanding Antibody Catalysis [14]	75
3.2.4	General Considerations	76
3.3	Hydrolytic Antibodies	76
3.3.1	Gas and Solution Phase Hydrolysis of Aryl Esters	76
3.3.2	Hapten Fidelity	78
3.3.3	Theoretical Exploration of Antibody Catalysis	80
3.3.3.1	16G3	81
3.3.3.2	6D9	82
3.3.3.3	43C9	83
3.3.3.4	CNJ206	84
3.3.3.5	48G7	85
3.3.3.6	17E8 and 29G11	86
3.4	Cationic Cyclizations	88
3.4.1	Antibody Catalysis of Solvolysis	88
3.4.2	Antibody-Catalyzed Hydroxyepoxide Cyclization	89
3.5	Antibody-Catalyzed Diels-Alder and <i>retro</i> -Diels-Alder Reactions	90
3.5.1	The Most Efficient <i>endo</i> -Diels-Alderase 1E9	91
3.5.2	<i>endo</i> -Diels-Alderase 39A11 and its Germline Precursor	93
3.5.3	<i>exo</i> -Diels-Alderase 13G5	96
3.5.4	<i>retro</i> -Diels-Alderase 10F11	100
3.6	Other Antibody-Catalyzed Pericyclic Reactions	101
3.6.1	Oxy-Cope Rearrangement Catalyzed by Antibody AZ-28	101
3.6.2	1,3-Dipolar Cycloaddition Catalyzed by Antibody 29G12	105
3.6.3	Chorismate-Prephenate Claisen Rearrangement Catalyzed by Antibody 1F7	106

3.7	Antibody-Catalyzed Carboxybenzoxazole Decarboxylation	107
3.8	Summary	110
	References	111
4	The Enterprise of Catalytic Antibodies: A Historical Perspective	118
	<i>Michael Ben-Chaim</i>	
4.1	Introduction	118
4.2	Methods	120
4.3	Results	122
4.3.1	The Conceptual Origins of Catalytic Antibodies	122
4.3.2	Tapping the Immune System for Catalysts	125
4.4	Conclusions	128
	References	130
5	Catalytic Antibodies in Natural Products Synthesis	132
	<i>Ashraf Brik, Ehud Keinan</i>	
5.1	Introduction	132
5.2	Total Synthesis of α -Multistriatin via Antibody-Catalyzed Asymmetric Protonolysis of an Enol Ether	134
5.3	Total Synthesis of Epothilones Using Aldolase Antibodies	136
5.4	Total Synthesis of Brevicomins Using Aldolase Antibody 38C2	142
5.5	Synthesis of 1-Deoxy-L-Xylose Using 38C2 Antibody	145
5.6	Synthesis of (+)-Frontalin and Mevalonolactone via Resolution of Tertiary Aldols with 38C2	145
5.7	Wieland-Miescher Ketone via 38C2-Catalyzed Robinson Annulation	147
5.8	Formation of Steroid A and B Rings via Cationic Cyclization	147
5.9	Synthesis of Naproxen via Antibody-Catalyzed Ester Hydrolysis	148
5.10	Conclusions	148
	References	150
6	Structure and Function of Catalytic Antibodies	153
	<i>Nicholas A. Larsen, Ian A. Wilson</i>	
6.1	Introduction	153
6.2	Electrostatic Complementarity	155
6.2.1	Anionic Binding Motifs and Ester Hydrolysis	155
6.2.2	Structural Motifs	156
6.2.3	Mechanistic Considerations	157
6.2.4	Mechanistic Pitfalls	158
6.2.5	Structural and Functional Considerations for Hapten Design	158
6.2.6	Anionic Binding Motifs and Control of the Microenvironment in Decarboxylation	159

- 6.2.7 Anionic Binding Motifs and the Periodate Cofactor in Sulfide Oxygenation 160
- 6.2.8 Cation Stabilization and Allylic Isomerization 161
- 6.3 Shape Complementarity and Approximation 162
 - 6.3.1 Unimolecular Rearrangements 163
 - 6.3.1.1 Antibody 1F7 163
 - 6.3.1.2 Antibody AZ-28 164
 - 6.3.2 Bimolecular Rearrangements and the Diels-Alder Reaction 165
 - 6.3.2.1 Retro-Diels-Alder Reaction 165
 - 6.3.2.2 Disfavored *exo* Diels-Alder Reaction 166
 - 6.3.2.3 *Endo* Diels-Alder Reactions 167
- 6.4 Shape Complementarity and Control of the Reaction Coordinate 169
 - 6.4.1 *Syn*-Elimination 169
 - 6.4.2 Disfavored Ring Closure 171
 - 6.4.3 Selective Control of a Reactive Carbocation: Antibodies 4C6 and 19A4 172
- 6.5 Shape Complementarity and Substrate Strain 174
- 6.6 Reactive Amino Acids and the Possibility of Covalent Catalysis 175
- 6.7 New Challenges 178
- References 179

7 Antibody Catalysis of Disfavored Chemical Reactions 184

Jonathan E. McDunn, Tobin J. Dickerson, Kim D. Janda

- 7.1 Introduction 184
- 7.2 Formal Violation of Baldwin's Rules for Ring Closure: the 6-*endo*-tet Ring Closure 185
- 7.3 Cationic Cyclization 191
 - 7.3.1 Initial Studies 191
 - 7.3.2 Tandem Cationic Cyclization Mediated by Antibody 197
- 7.4 *exo*-Diels-Alder Reactions 203
- 7.5 Miscellaneous Disfavored Processes 206
 - 7.5.1 *Syn*-Elimination to a *cis* Olefin 206
 - 7.5.2 Aryl Carbamate Hydrolysis via B_{Ac}2 Mechanism 207
 - 7.5.3 Transesterification 208
 - 7.5.4 Ketal Formation 210
 - 7.5.5 Controlling Photoprocesses 211
- 7.6 Summary 212
- References 214

8 Screening Methods for Catalytic Antibodies 217

Jean-Louis Reymond

- 8.1 Introduction 217
- 8.2 Theoretical Consideration: What to look for during screening 218
 - 8.2.1 Converting Antibody Binding to Catalysis (Quantitatively) 218

8.2.2	Screening and the Theoretical Detection Limits	219
8.2.3	The Proof of Selective Antibody Catalysis	220
8.3	A Practical Perspective: Screening in the Published Literature	221
8.3.1	Statistical Overview	221
8.3.2	HPLC Analysis	223
8.3.3	Chromogenic and Fluorogenic Reactions	225
8.4	High-Throughput Screening Methods	226
8.4.1	Enzyme-Coupled Assays	227
8.4.2	cat-ELISA	228
8.4.3	Thin-Layer Chromatography	230
8.4.4	Chromogenic and Fluorogenic Substrates	230
8.4.5	Isotopic Labeling	235
8.5	Examples with Fluorogenic Substrates and Antibodies from Hybridoma	235
8.5.1	Retro-Diels-Alderase Antibodies	236
8.5.2	Pivalase Catalytic Antibodies	237
8.6	Conclusion	239
	References	240

9 *In vitro* Evolution of Catalytic Antibodies and Other Proteins via Combinatorial Libraries 243

Ron Piran, Ehud Keinan

9.1	Introduction	243
9.2	Technologies and Constructs – Basic Principles	244
9.2.1	Phage Display	244
9.2.2	The Fab Construct	246
9.2.3	The Fv Construct	248
9.2.4	<i>In vitro</i> Immunization	250
9.3	Screening of Libraries	251
9.4	Directed Evolution	262
9.4.1	Mutagenesis and Selection	263
9.4.2	DNA Shuffling	267
9.5	<i>In vitro</i> Libraries	270
9.5.1	Ribosomal Display	270
9.5.2	<i>In vitro</i> Compartmentalization	271
9.5.3	Plasmid Display	272
9.6	<i>In vivo</i> Libraries	273
9.6.1	Protein Libraries Presented on an <i>E. coli</i> Surface	273
9.6.2	Protein Libraries in Yeast	274
9.6.3	Protein Libraries in Other Organisms	276
9.7	Conclusions and Outlook	279
	References	280

10	Medicinal Potential of Catalytic Antibodies 284
	<i>Roey Amir, Doron Shabat</i>
10.1	Introduction 284
10.2	Prodrug Activation 284
10.2.1	Catalytic Antibodies Designed for Carbamate/Ester Hydrolysis 284
10.2.2	Catalytic Antibody Designed for <i>retro</i> -Diels-Alder Reaction 287
10.2.3	Catalytic Antibody 38C2 (<i>retro</i> -Aldol- <i>retro</i> -Michael Cleavage Reaction) 288
10.3	Cocaine Inactivation 300
10.4	Conclusions 301
	References 302
11	Reactive Immunization: A Unique Approach to Aldolase Antibodies 304
	<i>Fujie Tanaka, Carlos F. Barbas, III</i>
11.1	Introduction 304
11.2	Generation of Aldolase Antibodies by Reactive Immunization 305
11.2.1	Development of the Concept of Reactive Immunization 305
11.2.2	Combining Reactive Immunization with Transition State Analog for Aldolase Antibodies 309
11.3	Structural Insight into Aldolase Antibodies 310
11.4	Aldolase Antibody-catalyzed Reactions 313
11.4.1	Broad Scope and High Enantioselectivity 313
11.4.2	Aldol Reactions Catalyzed by Aldolase Antibodies 38C2 and 33F12 314
11.4.3	Antibody 38C2 and 33F12-catalyzed <i>retro</i> -Aldol Reactions and Their Application to Kinetic Resolutions 315
11.4.4	Aldol and <i>retro</i> -Aldol Reactions Catalyzed by Aldolase Antibodies 93F3 and 84G3 316
11.4.5	Preparative scale kinetic resolutions using aldolase antibodies in a biphasic aqueous/organic solvent system 318
11.4.6	Aldolase Antibody-catalyzed Reactions in Natural Product Syntheses 318
11.4.7	Aldolase Antibodies in Reactions Involving Imine and Enamine Mechanisms and Exploitation of the Nucleophilic Lysine ϵ -Amino Group 319
11.4.8	Concise Catalytic Assays for Aldolase Antibody-catalyzed Reactions 321
11.4.9	Prodrug Activation by an Aldolase Antibody 322
11.5	Evolution of Aldolase Antibodies <i>in vitro</i> 325
11.5.1	Selection of Aldolase Antibodies with Diketones using Phage Display 325
11.5.2	Selection Systems for Aldolase Antibodies 328
11.6	Other Catalytic Antibodies Selected with Reactive Compounds <i>in vitro</i> 328
11.7	Summary 330
11.8	Acknowledgments 331
	References 332

12	The Antibody-Catalyzed Water Oxidation Pathway 336 <i>Cindy Takeuchi, Paul Wentworth Jr.</i> References 348
13	Photoenzymes and Photoabzymes 350 <i>Sigal Saphier, Ron Piran, Ehud Keinan</i>
13.1	Introduction 350
13.2	Photoenzymes 351
13.2.1	Protochlorophyllide Reductase 351
13.2.2	DNA Photolyase 352
13.2.3	[6-4] Photoproduct Lyase 355
13.2.4	General Considerations 356
13.3	Photocatalytic Antibodies 357
13.4	Conclusions 366
13.5	Acknowledgement 366 References 367
14	Selectivity with Catalytic Antibodies – What Can Be Achieved? 370 <i>Veronique Gouverneur</i>
14.1	Introduction 370
14.2	Acyl Transfer Reactions: Ester Hydrolysis, Transacylations, and Amide Hydrolysis 371
14.3	Glycosyl and Phosphoryl Group Transfer 383
14.4	Pericyclic Reactions 385
14.4.1	Sigmatropic Rearrangement 386
14.4.2	Pericyclic Eliminations 387
14.4.3	Cycloaddition 388
14.5	Aldol Reactions 392
14.6	Cyclization 398
14.6.1	Reduction and Oxidation 402
14.7	Additions and Eliminations 405
14.8	Conclusion 408 References 410
15	Catalytic Antibodies as Mechanistic and Structural Models of Hydrolytic Enzymes 418 <i>Ariel B. Lindner, Zelig Eshhar, Dan S. Tawfik</i>
15.1	Introduction 418
15.2	Chapter Overview 421
15.2.1	Catalysis by Oxyanion Stabilization (OAS) 421
15.2.1.1	Fidelity of TSA design 422
15.2.1.2	Esterolytic Antibodies Based Solely on Oxyanion Stabilization 422

- 15.2.1.3 Antibody Oxyanion Holes 425
- 15.2.1.4 Oxyanion holes – Antibodies vs. Enzymes 426
- 15.2.1.5 Antibody Affinity and Rate Acceleration Limitation 429
- 15.2.1.6 Nucleophilic Catalysis 430
- 15.2.2 Endogenous Nucleophiles in Hydrolytic Antibodies 431
- 15.2.2.1 Reactive immunization (RI) 431
- 15.2.2.2 Serendipity and 43C9 Antibody 432
- 15.2.3 Exogenous Nucleophiles and Chemical Rescue in Hydrolytic Antibodies 435
- 15.2.4 General Acid/Base Mechanisms in Hydrolytic Antibodies 439
- 15.2.5 Metal-Activated Catalytic Antibodies 441
- 15.2.6 Substrate Destabilization 442
- 15.3 The Role of Conformational Changes in Catalytic Antibodies 443
- 15.3.1 Conformational changes in catalytic antibodies 444
- 15.3.2 The contribution of structural isomerization to catalysis 445
- 15.4 Conclusions 447
- References 449

16 Transition State Analogs – Archetype Antigens for Catalytic Antibody Generation 454

Anita D. Wentworth, Paul Wentworth, Jr., G. Michael Blackburn

References 467

17 Polyclonal Catalytic Antibodies 470

Marina Resmini, Elizabeth L. Ostler, Keith Brocklehurst, Gerard Gallacher

- 17.1 Introduction 470
- 17.2 The Importance of Polyclonal Catalytic Antibodies 471
- 17.3 Demonstration of Polyclonal Antibody Catalysis 472
- 17.4 Hapten Design and Catalytic Antibody Activity 475
- 17.5 Kinetic Activity, Homogeneity, and Variability 477
- 17.6 Assessment of Contamination 478
- 17.7 Mechanistic Studies 480
- 17.8 Investigations of Active-Site Availability 480
- 17.9 Therapeutic Applications 481
- 17.10 Antiidiotypic Antibodies 484
- 17.11 Naturally-Occurring Catalytic Antibodies 484
- 17.12 Conclusions 485
- References 487

18 Production of Monoclonal Catalytic Antibodies: Principles and Practice 491

Diane Kubitz, Ehud Keinan

- 18.1 Introduction 491

18.2	Immunization	492
18.3	Hybridoma Production and Screening	494
18.4	Large-Scale Antibody Production	497
18.5	Antibody Purification	499
18.6	Testing for Catalytic Activity	500
18.7	Preparation of Fab, F(ab') ₂ , and Fab' Fragments	500
18.8	Conclusion	503
	References	504
19	Natural Catalytic Antibodies – Abzymes	505
	<i>Georgy A. Nevinsky, Valentina N. Buneva</i>	
19.1	Abbreviations	505
19.2	Introduction	505
19.3	Natural Catalytic Antibodies	506
19.4	Peculiarities of the Immune Status of Patients with Various Autoimmune Diseases	508
19.5	The Origin of Natural Autoimmune Abzymes	510
19.6	Peculiarities of the Immune Status of Pregnant and Lactating Women and the Origin of Natural Abzymes from Human Milk	513
19.7	Purification of Natural Abzymes	519
19.8	Criteria to Establish that Catalytic Activity is Intrinsic to Antibodies	525
19.9	Catalytic Antibodies Catalyzing Transformations of Water and Oxygen Radicals	530
19.10	Antibodies with Proteolytic Activities	531
19.10.1	Antibodies Hydrolyzing Vasoactive Intestinal Peptide	532
19.10.2	Abzymes Hydrolyzing Thyroglobulin, Prothrombin, and Factor VIII	533
19.11	Human and Animal RNase and DNase Abzymes	534
19.12	Human Milk Abzymes with Various Activities	542
19.12.1	Abzymes with Protein Kinase Activity	542
19.12.2	Abzymes with Lipid Kinase Activity	545
19.12.3	Abzymes with Oligosaccharide Kinase Activity	549
19.12.4	Nucleotide-Hydrolyzing Abzymes of Human Milk	551
19.12.5	Human Blood Sera and Milk Abzymes Hydrolyzing Polysaccharides	552
19.12.6	Peculiarities of Milk Abzymes	554
19.13	Biological Roles of Abzymes	555
19.14	Natural Abzymes as Tools for Investigating RNA Structure	557
19.15	Abzymes as Diagnostic Tools and Tools for Biological Manipulations	557
19.16	Conclusion	561
	References	562

“What I cannot create I do not understand.”
Richard P. Feynman

Preface

It is now 18 years since the first antibody catalysts elicited against transition-state analogs were induced. At this age of maturation we found it appropriate to comprehensively cover the field of antibody catalysis in one volume. The catalytic antibody technology merges the combinatorial diversity of the immune system with a programmable design by the experimenter. In fact, no other area of bioorganic chemistry has taught us so much about the use of large libraries of molecules in the service of chemistry. We have learned from the immune system that natural evolution does not necessarily require billions of years; it may be completed on a laboratory timescale. This lesson of applying the three major components of evolution – diversity, selection and amplification – has inspired biologists and chemists alike on their quest to discover new functional biopolymers, new catalysts, new drugs, and even new solid-state materials with desired physical properties.

There are many conceptual steps on the way towards the realization of a new antibody catalyst, including mechanistic understanding of the specific reaction to be catalyzed, scholarly prediction of the transition state of highest energy, creative design of a chemically stable transition state analog (TSA), and the planning of synthetic schemes for haptens and substrates. Yet, as is appropriately expressed by the above-cited dictum of Feynman, antibody catalysis is primarily an experimental science where the keys to success reside in the details of the experimental procedures, including organic synthesis, immunization protocols, screening procedures, production of monoclonal antibodies, kinetic experiments, and crystallographic studies.

Many facets of biocatalysis are not yet fully understood, particularly those related to the dynamics of the protein catalyst along the reaction coordinate. Even when some of that can be envisaged, we do not yet know how to design the antibody active site in order to achieve the desired dynamic properties. Therefore, the use of a TSA, even an optimal one, which is often impossible to make, represents only a “snapshot” of a continuous, dynamic process and only a general guideline for the immune system to produce the appropriate catalyst. The resultant, broadly diverse population of relevant antibodies reflects the variety of ways by which the immune system can respond to the given TSA. The beauty of this approach is the element of serendipity, allowing us to find valuable items that were not looked for. Consequently, the importance of efficient screening strategies can never be overestimated.

One of the most significant trends in modern science is the collapse of traditional barriers between well-defined scientific disciplines. Antibody catalysis has illustrated, probably more than any other field, the rewards of working at the interface of biology and chemistry. The diverse chapters of this book reflect the broad spectrum of activities in this highly interdisciplinary field.

Chapter 1 describes structural and functional studies of the immunological evolution of catalytic antibodies, which have provided important insights into the evolution of binding energy and catalysis in biological systems, including antibodies and enzymes. These studies suggest that there is an intrinsic conformational flexibility within the germline antibody combining site. The binding of ligands to the germline antibody induces conformational rearrangements that result in enhanced complementarity between the antibody and the ligand. Consequently, structural plasticity in the combining site allows a limited number of protein scaffolds to bind a broad array of substrates with moderate affinity. Then, somatic mutations and selection processes optimize the complementarity of the combining site with its hapten by fixing the conformation of the CDR loops. Interestingly, these mutations are introduced not only at the hapten combining site but also at the peripheries of that site.

Chapter 2 analyzes the main achievements in the field and defines the key challenges ahead of us. The chapter examines the structure and mechanism of representative catalytic antibodies that were generated by various strategies for different reaction types. It concludes that the field has progressed rapidly from simple model reactions to complex multistep processes, thus defining the scope and limitations of this technology. Now that the approach is well established, attention must be paid to strategies for optimizing catalytic efficiency and for promoting more demanding transformations. Development of improved transition-state analogues, refinements in immunization and screening protocols, and elaboration of general strategies for enhancing the efficiency of first-generation catalytic antibodies are identified as evident, but difficult, challenges for this field. In addition, learning how to create, manipulate and evolve large combinatorial libraries of proteins outside the immune system should help to automate the processes of catalyst discovery and optimization.

Chapter 3 reviews the theoretical studies that have been performed on antibody catalysis to date. Various tools have been applied to the computational investigations of different types of reactions that have been catalyzed by antibodies. Many insights about both quantitative and qualitative aspects of antibody catalysis have been obtained. It may be concluded that quantum mechanical computations on model systems can now be carried out with high accuracy, affording good qualitative determinations of the mode of binding of haptens, substrates, and transition states into antibody binding sites. Yet, the major challenges to be met on the way to a full understanding of antibody catalysis in particular, and biocatalysis, in general, include the development of practical quantitative computation methods for solvation energies and protein-ligand interaction energies.

Chapter 4, which is written by a science historian, brings in to this book a unique historical perspective of the field, drawing special attention to the initial endeavors

to establish antibody catalysis as a scientific discipline at the crossroads of chemistry and immunology. The chapter is neither a comprehensive coverage of the history of the field and the chronological development nor a presentation of the key individuals who contributed to the field. It treats the emergence of this field as a case study and a model for what does it take for a new scientific discipline to be born. Dr. Ben Chaim's thesis is based on many hours of recorded interviews with almost all the active scientists in the field. I believe that this rather unusual, thought-provoking contribution blends well with the scientific chapters of this book.

Chapter 5 covers the use of catalytic antibodies in the synthesis of natural products. One of the main goals of the field of antibody catalysis has been to learn how to design catalysts to improve the overall yield of existing synthetic routes, thus allowing practical construction of more totally synthetic drugs and other important natural products. The examples covered by this chapter, including (–)- α -multistriatin, epotilones, brevicomis, 1-deoxy-1-xylose, (+)-frontalin, the formal synthesis of (–)- and (+)-mevalonolactone, partial synthesis of the steroid skeleton, and naproxen, testify for the important role catalytic antibodies may play in asymmetric synthesis. The remarkable ability of these biocatalysts to control the rate, stereo-, regio-, chemo-, and enantioselectivity of many reactions, including highly disfavored chemical processes, and sometimes even with high substrates promiscuity, render these agents valuable tools for the total synthesis of pharmaceuticals, fine chemicals, and complex natural products.

Chapter 6 presents an impressive number of X-ray crystallographic studies of catalytic antibodies, which have provided valuable descriptions of the specific interactions with substrates and TSAs within the antibody combining sites. The antibodies studied catalyze a variety of chemical transformations, including ester hydrolysis, Diels-Alder reaction, cationic cyclization, elimination, decarboxylation, aldol reactions, sulfide oxidation, rearrangements, and metal chelation. This chapter catalogues and critically assesses the contributions that structural studies have made to the understanding of the catalytic mechanism. Comparisons are made to natural enzymes that catalyze similar reactions.

Chapter 7 reviews several remarkable cases of antibody-catalyzed disfavored chemical transformations. Catalysis of such reactions is a most compelling aspect in both enzymes and catalytic antibodies not only because the reactions are synthetically useful but also because these biocatalysts reveal how nature solves particularly difficult problems. Biochemical and structural studies of the enzymes and antibodies that catalyze disfavored reactions provide chemists with insights into important mechanistic considerations as well as a starting point in the development of *de novo* catalysts for these and other disfavored processes. The examples covered in this chapter include formal violation of the Baldwin's rules for ring closure, exo-Diels-Alder reactions, formation of a ketal in water, *syn*-elimination to produce a cis olefin, and selective formation of C-C bonds via cationic cyclization reactions.

Chapter 8 underscores the importance of screening methods for catalytic antibodies. Selective transition state binding is just one of many elements of catalysis, one that

can be well designed by immunization with an appropriate TSA. Therefore, a good TSA-binder may not necessarily be a good catalyst. Although screening for binding is easily performed by the well-established immunological methods, one should keep in mind that this approach is reminiscent of searching for a lost coin under the street lamp. Certainly, the optimal approach would be the screening for actual catalysis rather than for binding.

Chapter 9 highlights the strengths of directed evolution for the design of novel enzymes with emphasis on catalytic antibodies. The representative techniques of displayed combinatorial protein libraries that are described in this chapter do not cover the entire field of directed evolution. They demonstrate, however, the great opportunities in the employment of such techniques for the development of functional proteins, and of catalytic antibodies in particular. The various strategies harness a number of important technologies, including the methods of cloning and expression of Fab and scFv in different organisms, the ways of physically linking the phenotype to its genotype, the means of creating large libraries in very small volumes, methods of clone selection, and techniques of amplification of clones having the desired properties.

Chapter 10 reviews the medicinal applications of catalytic antibodies, particularly for prodrug activation. The addition of a targeting device to the relevant catalytic antibody renders this treatment highly selective for tumor cells, thus allowing the conversion of a nontoxic prodrug into a toxic drug in high local doses at the tumor site. The concept of using catalytic antibodies as therapeutic agents has become even more appealing when it was shown that most of the amino acids in a mouse antibody molecule could be replaced with human sequences, thereby making it compatible for *in vivo* treatment in humans. Furthermore, since antibodies can catalyze specific reactions that are not catalyzed by natural enzymes they can be used *in vivo*, avoiding specific catalytic competition with natural proteins.

Chapter 11 discusses the development of the concept of reactive immunization and its application to the creation of aldolase antibodies *in vivo*. The *in vitro* application of this strategy can be achieved using phage display selections with reactive compounds. Reactive immunization *in vivo* and reactive selection *in vitro* utilize designed reactive compounds that covalently react with antibodies during their induction and selection in such a way as to effectively program a reaction mechanism into the selected protein. The direct consequence of this strategy is the development of efficient catalysts that operate via experimenter-defined mechanisms. This approach has provided highly proficient aldolase antibodies that had not been accessible by traditional immunization with transition state analogs. Broad scope, enhanced catalytic activity, and defined chemical mechanism are three features that distinguish antibodies derived from reactive immunization from those obtained by immunization with transition state analogs.

Chapter 12 is devoted to the newly discovered antibody-catalyzed water oxidation pathway. A central concept within immunology is that antibodies are the key molecular link between recognition and destruction of antigens/pathogens. The antibody catalysis field has demonstrated that the antibody molecule is capable of performing

sophisticated chemistry, but there was no compelling evidence that antibodies use this catalytic potential in their normal immune function. It was found recently that all antibodies, regardless of source or antigenic specificity, can catalyze the oxidation of water by singlet oxygen via a pathway, which is postulated to include trioxxygen species such as dihydrogen trioxide and ozone, to the ultimate product, hydrogen peroxide. It has been shown that oxidants generated by antibodies and by activated human neutrophils, which are present in inflammatory tissues, can kill bacteria.

Chapter 13 describes the known enzymes and antibodies that catalyze photochemical reactions. Biocatalysis is an attractive and useful strategy by which mechanistic manifolds can be restrained and a reactive intermediate such as excited species in photochemical reactions can be channeled into a single product. The lesson we learn from the very few known natural photoenzymes shows that catalysis originates mainly from entropic stabilization of a productive conformer and from the involvement of a photoactive group. Such groups may be available in the form of either a cofactor or an amino acid residue. The few reported examples of photocatalytic antibodies have demonstrated that this approach can be utilized successfully for the design of novel photocatalysts and this opportunity should be considered seriously, particularly because natural evolution has voted against the development of photocatalytic enzymes.

Chapter 14 highlights the high selectivity of catalytic antibodies, including chemo-, regio-, stereoselectivity, and, in particular, enantioselectivity. The ability of antibodies to discriminate between closely related isomeric transition states have been utilized in asymmetric synthesis and other selective transformations, some of which have no enzymatic equivalent.

Chapter 15 analyzes various examples of catalytic antibodies as mechanistic and structural models of hydrolytic enzymes, emphasizing the ability of antibodies to mimic multiple aspects of enzyme catalysis. Undoubtedly, these research efforts have created unique opportunities to learn about enzyme structure and function, about antibody diversity, and about evolution. Although hydrolytic catalytic antibodies have shown high selectivity, they are still inferior to natural enzymes in terms of catalytic efficiency. It is relatively easy to install in antibodies individual parameters of a catalytic machinery but it is still very difficult to design an optimal catalyst having all catalytic elements operating in concert, including the relative positioning of catalytic residues and the appropriate protein dynamics. The obvious consequence is that the keys for obtaining better catalysts are screening methods for catalysis and techniques of directed evolution.

Chapter 16 focuses on the use of transition state analogs as archetype antigens. Many catalytic antibodies elicited against TSAs have rarely approached the catalytic efficiency of enzymes. Yet, from a pragmatic perspective, the achievement of enzyme-like efficiency is not the ultimate condition for a satisfactory catalytic activity either *in vitro* or *in vivo*. From a chemist's point of view, the ability to program an antibody to catalyze reactions for which there is no enzymatic counterpart, such as the Diels-Alder cycloaddition, the 1,3-dipolar cycloaddition, or the Bergman cycloaromatization

reaction, with reasonable rate enhancement and with high regio-, chemo-, stereo-, and enantioselectivity, is a good reason to continue exploring the scope of these remarkable biocatalysts.

Chapter 17 highlights the advantages of using polyclonal catalytic antibodies, which, in contrast with antibodies produced by the hybridoma technology, represent the entirety of the immune response. The study of polyclonal catalytic antibodies has already contributed significantly to the understanding of how the immune system works and of the requirements for successful hapten design. Recently this has led to interesting developments in therapeutic applications, both by active or passive immunization.

Chapter 18 is devoted to the experimental work that is needed for the general production and purification of catalytic monoclonal antibodies via the hybridoma technology. Since antibody catalysis is primarily an experimental science, the keys to success reside in the details of the experimental procedures. Although hybridoma technology is a mature and well-established method, it involves a variety of independent variables and steps. Each step can be carried out in many different ways, and the diversity of the published approaches reflects specific biological problems and experimental tradition that characterize any given laboratory. The literature offers a broad variety of methods, which differ from one another in speed, convenience, reproducibility, and cost. The immunization protocols and the methods of producing monoclonal antibodies described in this chapter have been used continuously over the past two decades in our Scripps laboratories, without claiming that these methods are superior to others.

Finally, **Chapter 19** focuses on naturally occurring catalytic antibodies, which have been surprisingly discovered in the immune system. Such catalysts could function as important mediators of the immunological defense, regulation, and autoimmune dysfunction.

Due to the page limit of this volume, these nineteen chapters describe only some of the most important aspects but certainly do not cover fully the entire science of catalytic antibodies. Likewise, not all the active researchers in the field could be represented in this book. I thank the authors who agreed to participate in this endeavor for their contribution and insight and apologize to the many other scientists who could not be included in the project. It is my hope that this volume will stimulate further research and attract young scientists to join the intriguing field of catalytic antibodies.

List of Contributors

Roey Amir

Department of Organic Chemistry
Faculty of Exact Sciences
Tel-Aviv University
Tel-Aviv, 69978
Israel

Carlos F. Barbas, III

Department of Molecular Biology
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037
USA
carlos@scripps.edu

Michael Ben-Chaim

48 McKeel Avenue
Tarrytown, NY 10591
USA

G. Michael Blackburn

Department of Chemistry
University of Sheffield
Sheffield S3 7HF
United Kingdom

Ashraf Brik

Department of Chemistry
Technion-Israel Institute of Technology
Technion City

Haifa 32000

Israel

Keith Brocklehurst

School of Biological Sciences
Queen Mary, University of London
Mile End Road
London E1 4NS
United Kingdom

Valentina N. Buneva

Institute of Chemical Biology and Funda-
mental Medicine
Siberian Division of Russian Academy of
Sciences
8, Lavrentiev Ave.
Novosibirsk 630090
Russia

Tobin J. Dickerson

Department of Chemistry
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037
USA

Zelig Eshhar

Department of Immunology
Weizmann Institute of Science
POB 26

Rehovot 76100
Israel

Gerard Gallacher

School of Pharmacy and Biomolecular
Sciences
University of Brighton
Cockcroft Building, Moulsecoomb
Brighton BN2 4GJ
United Kingdom

Veronique Gouverneur

University of Oxford
The Central Chemistry Laboratory
South Parks Road
OX1 3QH Oxford
United Kingdom
veronique.gouverneur@chem.ox.ac.uk

Donald Hilvert

Laboratory of Organic Chemistry
Swiss Federal Institute of Technology
Universitätsstrasse 16
CH-8092 Zürich
Switzerland
hilvert@org.chem.ethz.ch

Kendall N. Houk

Department of Chemistry and Bioche-
mistry
University of California, Los Angeles
405 Hilgard Ave.
Los Angeles, CA 90095-1569
USA
houk@chem.ucla.edu

Kim D. Janda

Department of Chemistry
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037
USA
kdjanda@scripps.edu

Ehud Keinan

Department of Chemistry
Technion-Israel Institute of Technology
Technion City
Haifa 32000
Israel
keinan@techunix.technion.ac.il

Diane Kubitz

Department of Chemistry
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037
USA
dkubitz@scripps.edu

Nicholas A. Larsen

Harvard Medical School
250 Longwood Ave. SGM123
Boston, MA 02115
USQ

Andrew G. Leach

Astrazeneca Pharmaceuticals
Mereside Alderley Park
Macclesfield SK10 4TG
United Kingdom

Richard A. Lerner

Department of Chemistry
The Scripps Research Institute
10550 North Torrey Pines Road
La Jolla, CA 92037
USA
rlerner@scripps.edu

Ariel B. Lindner

Department of Immunology
Weizmann Institute of Science
POB 26
Rehovot 76100
Israel

Jonathan E. McDunn

Department of Chemistry